Edgewise launches children’s trial for muscular dystrophy drug
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has initiated a study of the impact of its flagship muscular dystrophy drug candidate EDG-5506 on children with Duchenne Muscular Dystrophy.
The Phase 2 clinical trial is being conducted at Rare Disease Research LLC in Atlanta. Test subjects are 27 children ages 4 to 9 years.
“We are very pleased to begin this important clinical trial of EDG-5506,” Han C. Phan, head of research at Rare Disease Research LLC, said in a prepared statement. “Having studied EDG-5506 over the past year in individuals with Becker with promising results, I’m excited to see the potential of EDG-5506 in children with Duchenne.”
SPONSORED CONTENT
The many benefits of simple, coordinated healthcare
Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.
